This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Roche Holding AG
Drug Names(s): dornase alfa, rhDNase
Description: DNA builds up in the lungs of patients with cystic fibrosis and contributes to the increased viscosity of secretions seen in this disorder. Pulmozyme is a recombinant formulation of DNAse, an enzyme that digests DNA. Pulmozyme is inhaled into the lungs, where it breaks down the DNA in the sputum, reducing its viscosity and other characteristics that impair patients' pulmonary function. Daily administration of Pulmozyme in conjunction with standard therapies is indicated in the management of cystic fibrosis patients to improve pulmonary function.
Deal Structure: Genentech markets Pulmozyme in the U.S., U.K., Germany, the Netherlands, and Ireland. Roche markets Pulmozyme in the remaining European countries.
In March 2009, Roche and Genentech announced that they signed a merger agreement under which Roche will acquire the outstanding publicly held interest in Genentech for US95.00 per share in cash, or a total payment of approximately US$46.8 billion to equity holders of Genentech other than Roche. The acquisition was completed on March 26, 2009.
Partners: Chugai Pharmaceutical Co., Ltd.
Additional information available to subscribers only: